ClinicalTrials.gg
RecruitingNCT02982902Updated Oct 22, 2025

T Cell Therapy of Opportunistic Cytomegalovirus Infection

An Early Phase 1 interventional study of CMV specific adoptive t-cells in Cytomegalovirus Infections, Hematopoietic Stem Cell Transplant and Opportunistic Infections, sponsored by Mari Dallas. Recruiting at 1 site in United States. Open to participants aged 3 Months and older. Per ClinicalTrials.gov, last updated 2025-10-22.

Sponsored by Mari Dallas · Early Phase 1, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started May 2020; still recruiting 6 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
3 Months and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 178 studies in Cytomegalovirus Infections with a site in United States — 15 open to participants now, 21 under way, 2 of them phase 3. Cytomegalovirus Infections · United States.

Planned enrollment
114th of 139
20 · median 61
Started
2020
with 5 others
Phase 1
41 of 178
3 open now
Primary completion
2027-08
later than 9 of 20 live
Registered
127th of 178
by date

Among the 178 studies in Cytomegalovirus Infections with a site in United States, this one is the 114th largest by planned enrollment of the 139 interventional ones that give a count, is one of 6 that started in 2020, is one of 41 in phase 1, reaches primary completion later than 9 of the 20 other live ones, and was the 127th registered.

Cytomegalovirus Infections

370 studies on the registry are indexed under Cytomegalovirus Infections; 57 are open to participants now.

Browse Cytomegalovirus Infections studies →

Open to participants now

15 of the 178 studies in Cytomegalovirus Infections with a site in United States are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 35 Cytomegalovirus Infections studies recruiting now, 20 (57%) set no upper age limit and 13 (37%) stop at 75 or younger; 19 take children under 18; 2 take healthy volunteers.

This study: 3 Months and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 178 studies in Cytomegalovirus Infections with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine if a specific type of cell-based immunotherapy, using T-cells from a donor that are specific against cytomegalovirus (CMV) is feasible to treat infections by CMV.

Adoptive T-cell therapy is an investigational (experimental) therapy that works by using the blood of a donor and selecting the T-cells that can respond against a specific infectious entity. These selected T-cells are then infused to the patient, to try to give the immune system the ability to fight the infection. Adoptive T-cell therapy is experimental because it is not approved by the Food and Drug Administration (FDA).

Read the detailed description

The primary objective of this study is to determine the feasibility of the treatment of opportunistic cytomegalovirus (CMV) infections after hematopoietic stem cell transplant (HSCT) with virus-specific, antigen-selected T-cells, selected using the CliniMACS prodigy system.

Secondary Objective(s)

  • To describe the safety profile of the infusion of CMV- specific, antigen selected T-cells.
  • To describe the toxicities related to infusion of CMV- specific, antigen selected T-cells.
  • To describe the rate of eradication of opportunistic CMV infections after HSCT and and treatment with CMV-specific, antigen-selected T-cells using the CliniMACS Prodigy System.

This feasibility study will include a single treatment cohort.

03

Conditions studied

  • Cytomegalovirus Infections
  • Hematopoietic Stem Cell Transplant
  • Opportunistic Infections

Keywords

  • Immunotherapy
  • T-Cell Therapy
  • Lymphoproliferative Disorder
04

Who can participate

Ages eligible
3 Months and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have received hematopoietic stem cell transplant and be greater than 30 days post-transplant at the time of registration
  • Patients must have documented opportunistic CMV infection, or reactivation; the criteria include (both of the following criteria must be met)

    • Patients may have asymptomatic viremia (>1000 copies/ml) OR presence of symptoms secondary to CMV infection, AND
    • Patients must have ONE OF THE NEXT FOUR CRITERIA:

      • Absence of an improvement of viral load after ≥ 14 days of antiviral therapy with ganciclovir, valganciclovir or foscarnet (decrease by at least 1 log, i.e. 10-fold) or
      • New, persistent and/or worsening CMV-related symptoms, signs and/or markers of end organ compromise while on antiviral therapy with ganciclovir, valganciclovir or foscarnet, or
      • Have or experience adverse effects of antiviral therapy with ganciclovir, valganciclovir or foscarnet.
      • Second recurrence of CMV viremia, CMV-related symptoms, signs and/or markers of end organ compromise.
  • (ECOG) performance status ≤ 3
  • Women of and men must agree to use adequate (double barrier method of birth control or abstinence) 4 weeks prior to study entry, for the duration of study participation and for 3 months after completing treatment.
  • Subjects must have the ability to understand and the willingness to sign a written document, or assent document.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding women are excluded from this study.
  • Patients with opportunistic viral infections other than CMV.
  • Patients with active, grade 2-4, acute graft vs. host disease (), chronic GVHD or any condition requiring high doses of glucocorticosteroid (>0.5 mg/kg/day prednisone or its equivalent) as treatment
  • Treatment with antithymocyte globulin within 28 days of planned infusion of virus - specific, antigen selected T cells.
  • Treatment with virus - specific T cells within 6 weeks (42 days) of planned infusion.

Donor eligibility

  • Related donor of T cells must be at least partially HLA compatible, matching with recipient in at least 3/6 HLA loci (HLA-A, HLA-B, and HLA-DRB1 loci will be considered for this).
  • Must have evidence of a serologic response (i.e. be seropositive) against CMV.
  • Age ≥ 18 years
  • Must meet the criteria for donor selection defined in the Standard Operating Procedures of University Hospitals Seidman Cancer Center Stem Cell Transplant Program
  • Must be capable of undergoing a single standard 2 blood volume leukapheresis or donation of one unit of whole blood
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

05

Study design

Phase
Early Phase 1
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    CMV specific adoptive t-cells

    This study involves a one-time infusion of the experimental CMV specific adoptive t-cells. After this infusion, patients will be followed for 4 weeks.

    Biological: CMV specific adoptive t-cells

Interventions

  • BiologicalCMV specific adoptive t-cells

    It is expected that the cell dose will be in the range of 10\^3 - 10\^5 virus - specific, antigen selected T cells per kg of recipient weight.

    Also known as: immunotherapy

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events

    To determine the feasibility of the intervention, the study will record the incidence of adverse events, including graft versus host disease and other complications will be evaluated using binomial distribution theory and their 95% confidence intervals (CIs) will be also estimated using Wilson's method

    Time frame: Up to 100 days after transplant

Secondary outcomes

  1. Eradication rate of opportunistic CMV infections

    The eradication rate will be the disappearance of opportunistic CMV infections with the use of CMV-specific, antigen-selected T cells using the CliniMACS Prodigy System over the total number CMV infections.

    Time frame: Up to 100 days after transplant

  2. response rate

    A response rate of 25% is considered unacceptable; and the anticipated response rate is approximately 55% for the study population using the cell therapy.

    Time frame: Up to 100 days after transplant

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2020 (actual). Primary completion is estimated for Aug 2027, 87 months after the start.

Of 21 phase 1 interventional studies under Cytomegalovirus Infections, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 45. This study's planned 87 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2016
First posted
Dec 6, 2016
StartActual
May 27, 2020
Primary completionEst.
Aug 2027
CompletionEst.
Aug 2028
Last update
Oct 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02982902
Lead sponsor
Mari Dallas
Responsible party
Mari Dallas (Principal Investigator, Case Comprehensive Cancer Center) — Sponsor-investigator
First posted
Dec 6, 2016
Start date
May 27, 2020
Primary completion
Aug 2027 (estimated)
Completion
Aug 2028 (estimated)
Last update
Oct 22, 2025

Study contacts

Mari H Dallas, MD
Contact
CTUReferral@UHhospitals.org
1-800-641-2422
Mari H Dallas, MD
principal investigator · University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion